Principal Financial Group Inc. Has $5.37 Million Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Principal Financial Group Inc. raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 89,961 shares of the specialty pharmaceutical company’s stock after buying an additional 5,829 shares during the quarter. Principal Financial Group Inc. owned 0.43% of ANI Pharmaceuticals worth $5,367,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after acquiring an additional 579 shares in the last quarter. XTX Topco Ltd purchased a new position in ANI Pharmaceuticals in the second quarter valued at about $207,000. HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals in the 3rd quarter worth about $222,000. Profund Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth about $225,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $228,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 2.0 %

ANIP opened at $55.28 on Thursday. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The business has a 50 day moving average of $57.09 and a 200-day moving average of $59.39. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -100.51 and a beta of 0.73. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period last year, the business posted $1.05 EPS. The business’s quarterly revenue was up 12.5% on a year-over-year basis. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on ANIP. Truist Financial increased their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, Raymond James upped their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,231 shares of company stock worth $2,434,286. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.